News Category
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a firs...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports knee cartilage regeneration, with European approval and a...
American Fusion's Texatron fusion program has entered a more demanding test phase, achieving record pressures and attracting new equity research cover...
InvestorWire announces its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, highlighting the event's ro...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, highlighting its role in build...
A new study confirms that treating selected ER patients while seated, rather than waiting for a bed, significantly reduces wait times, potentially lea...
Helus Pharma's completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder brings the company closer to a p...
Helus Pharma's appointment of Michael Halstead, a seasoned biopharmaceutical leader, signals strategic preparation for the potential commercialization...
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising $2.5 million to fund its first-in-human clinical trials ...
Shareholders of VERAXA Biotech AG approved key corporate governance and financing proposals with over 99.94% support, enabling greater flexibility for...
VERAXA Biotech AG announced its bispecific ADC program VXA-222 has passed a key technical milestone under its OmniAb collaboration, moving the precisi...
Gerresheimer has commenced operations at a new state-of-the-art plant in Zhenjiang Dagang, China, doubling its production capacity for primary packagi...
Darwin AG has changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market presence and recogniti...
NanoViricides progresses its oral gummies formulation of NV-387 toward a Phase II clinical trial for the Bundibugyo ebolavirus outbreak in the DRC, of...
Redwood AI Corp. has been included in the CSE25 Index, reflecting its growth in AI-driven chemistry and drug development, which may enhance its profil...
Helus Pharma reported fiscal 2026 financial results, highlighting over 88% enrollment in its Phase 3 APPROACH trial for HLP003, with topline data expe...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which aims to repair myelin damage in mul...
The article explores how advanced drug delivery technologies, exemplified by Oncotelic Therapeutics' Deciparticle platform, are poised to revolutioniz...
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis, progresses to Phase 2 trials after promising Phase 1 re...
VERAXA Biotech announced new in vitro proof-of-concept data showing its BiTAC-ADC platform can selectively kill breast cancer cells while sparing heal...
Redwood AI Corp. is highlighted as a company to watch due to its AI-powered platforms that aim to accelerate chemistry research and development in pha...
NanoViricides announced approval from the DRC Pillar Committee to conduct a Phase II trial of its oral NV-387 Gummies for Bundibugyo ebolavirus, highl...
Helus Pharma's Chief Medical Officer will discuss the company's novel serotonergic agonists in a fireside chat at the H.C. Wainwright Neuro Perspectiv...
Onco-Innovations Limited has initiated process development and scale-up for its proprietary drug candidate ONC010, a key step toward IND-enabling stud...
Quantum BioPharma advances LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, after successful Phase 1 trials and FDA Investigational ...
NeuroOne Medical Technologies will showcase its OneRF platform and provide commercialization updates at the Planet MicroCap Las Vegas Conference on Ju...
GeoVax Labs' CEO comments on recent pharmaceutical acquisitions signaling a strategic shift toward vaccine innovation, health security, and manufactur...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by reversing nerve damage, while its commercial product u...
Helus Pharma announces participation in the Jefferies Global Healthcare Conference, where interim CEO Eric So will discuss the company's Phase 3 and P...
TransCode Therapeutics has launched a Phase 2a trial of its lead candidate TTX-MC138 in colorectal cancer patients with minimal residual disease, aimi...
NanoViricides highlights its broad-spectrum antiviral candidate NV-387 as a potential treatment for the Bundibugyo Ebola outbreak, citing its unique h...
SureNano Science Ltd. enters the competitive GLP-1 obesity treatment market with its licensed peptide GEP-44, aiming to offer improved tolerability an...
Oncotelic Therapeutics (OTLC) has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself as a key player in the AI-dr...
Peer-reviewed data shows Telomir-Zn improves survival and reduces liver copper in Wilson’s disease models, bolstering the company's pipeline.
The FDA's no-objection to Lantern Pharma's protocol amendments for the LP-300 HARMONIC trial clarifies the regulatory path, potentially accelerating a...
NanoViricides (NYSE American: NNVC) emphasizes the potential of its oral broad-spectrum antiviral candidate NV-387 in response to the Bundibugyo Ebola...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the midpoint enrol...
LIXTE Biotechnology Holdings announced its first-quarter 2026 results, highlighting continued advancement of its lead oncology candidate LB-100 and st...
Dogwood Therapeutics announced first quarter 2026 financial results, highlighting progress in its pain treatment pipeline with Halneuron Phase 2b data...
Breakthroughs in blood-brain barrier penetration, such as Oncotelic's intranasal nose-to-brain system, are poised to revolutionize CNS drug delivery, ...
Silo Pharma (NASDAQ: SILO) announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, ...
Three hantavirus fatalities on the MV Hondius cruise ship highlight the risks of this rare infection and underscore the need for diagnostic tools deve...
NanoViricides announced FDA Orphan Drug Designation for NV-387 for measles, offering incentives and supporting development amid increasing global outb...
VolitionRx announces a technical milestone in detecting nucleosomes from capillary blood in sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma collaborates with TARA Mind and VETS to enhance clinical trial recruitment for its Phase 3 PARADIGM study, leveraging veteran networks to...
Ventripoint's VMS+ 4.0 system has been submitted for NMPA approval in China via the green channel, potentially accelerating access to AI-driven cardia...
Formycon AG will publish its FY 2025 results on April 22, 2026, and participate in several international investor conferences, highlighting its biosim...
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists, has appointed Dr. Ken Kramer as senior vice president of...
